SUTRO BIOPHARMA, INC. Depreciation and Amortization
SUTRO BIOPHARMA, INC. (STRO) reported Depreciation and Amortization of $2.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. depreciation, depletion and amortization for the quarter ending 2026-06-30 was $1.26M, a 33.58% decline year-over-year.
- SUTRO BIOPHARMA, INC. depreciation, depletion and amortization for the quarter ending 2026-03-31 was $1.28M, a 32.74% decline year-over-year.
- SUTRO BIOPHARMA, INC. depreciation, depletion and amortization for the quarter ending 2025-12-31 was $1.62M, a 13.06% decline year-over-year.
- SUTRO BIOPHARMA, INC. depreciation, depletion and amortization for the quarter ending 2025-09-30 was $1.90M, a 5.61% increase year-over-year.
- SUTRO BIOPHARMA, INC. depreciation, depletion and amortization for fiscal 2025 was $7.32M, a 1.47% increase from fiscal 2024.
- SUTRO BIOPHARMA, INC. depreciation, depletion and amortization for fiscal 2024 was $7.22M, a 5.90% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. depreciation, depletion and amortization for fiscal 2023 was $6.82M, a 19.79% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. depreciation, depletion and amortization for fiscal 2022 was $5.69M, a 17.46% increase from fiscal 2021.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.54M 10-Q · filed 2026-08-12 | $4.16M derived: sum of 3 quarters · filed 2026-08-12 | $6.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.28M 10-Q · filed 2026-05-14 | $2.90M derived: sum of 2 quarters · filed 2026-05-14 | $4.80M derived: sum of 3 quarters · filed 2026-05-14 | $6.70M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.52M derived: sum of 2 quarters · filed 2026-03-23 | $5.42M derived: sum of 3 quarters · filed 2026-08-12 | $7.32M 10-K · filed 2026-03-23 |
| 2025-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.80M derived: sum of 2 quarters · filed 2026-08-12 | $5.70M 10-Q · filed 2025-11-06 | $7.57M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $3.80M 10-Q · filed 2026-08-12 | $5.67M derived: sum of 3 quarters · filed 2026-08-12 | $7.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.90M 10-Q · filed 2026-05-14 | $3.77M derived: sum of 2 quarters · filed 2026-05-14 | $5.57M derived: sum of 3 quarters · filed 2026-05-14 | $7.36M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.67M derived: sum of 2 quarters · filed 2026-03-23 | $5.46M derived: sum of 3 quarters · filed 2026-03-23 | $7.22M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.59M derived: sum of 2 quarters · filed 2025-11-06 | $5.35M 10-Q · filed 2025-11-06 | $7.08M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.55M 10-Q · filed 2025-08-07 | $5.28M derived: sum of 3 quarters · filed 2025-08-07 | $7.02M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.76M 10-Q · filed 2025-05-08 | $3.49M derived: sum of 2 quarters · filed 2025-05-08 | $5.23M derived: sum of 3 quarters · filed 2025-05-08 | $6.96M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.47M derived: sum of 2 quarters · filed 2025-03-13 | $5.20M derived: sum of 3 quarters · filed 2025-03-13 | $6.82M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.47M derived: sum of 2 quarters · filed 2024-11-13 | $5.08M 10-Q · filed 2024-11-13 | $6.61M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $3.35M 10-Q · filed 2024-08-13 | $4.87M derived: sum of 3 quarters · filed 2025-03-13 | $6.31M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $1.61M 10-Q · filed 2024-05-13 | $3.14M derived: sum of 2 quarters · filed 2025-03-13 | $4.58M derived: sum of 3 quarters · filed 2025-03-13 | $5.98M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.97M derived: sum of 2 quarters · filed 2025-03-13 | $4.36M derived: sum of 3 quarters · filed 2025-03-13 | $5.69M 10-K · filed 2025-03-13 |
| 2022-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.83M derived: sum of 2 quarters · filed 2023-11-13 | $4.16M 10-Q · filed 2023-11-13 | $5.48M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.72M 10-Q · filed 2023-08-10 | $4.04M derived: sum of 3 quarters · filed 2024-03-25 | $5.16M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $1.33M 10-Q · filed 2023-05-15 | $2.64M derived: sum of 2 quarters · filed 2024-03-25 | $3.76M derived: sum of 3 quarters · filed 2024-03-25 | $4.88M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $2.43M derived: sum of 2 quarters · filed 2024-03-25 | $3.55M derived: sum of 3 quarters · filed 2024-03-25 | $4.84M 10-K · filed 2024-03-25 |
| 2021-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.24M derived: sum of 2 quarters · filed 2022-11-08 | $3.53M 10-Q · filed 2022-11-08 | $4.70M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.41M 10-Q · filed 2022-08-08 | $3.58M derived: sum of 3 quarters · filed 2023-03-30 | $4.55M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | $1.29M 10-Q · filed 2022-05-09 | $2.46M derived: sum of 2 quarters · filed 2023-03-30 | $3.43M derived: sum of 3 quarters · filed 2023-03-30 | $4.49M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $2.14M derived: sum of 2 quarters · filed 2023-03-30 | $3.20M derived: sum of 3 quarters · filed 2023-03-30 | $4.30M 10-K · filed 2023-03-30 |
| 2020-09-30 | $967.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.03M derived: sum of 2 quarters · filed 2021-11-10 | $3.13M 10-Q · filed 2021-11-10 | $4.34M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $2.16M 10-Q · filed 2021-08-09 | $3.38M derived: sum of 3 quarters · filed 2022-02-28 | $4.61M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.10M 10-Q · filed 2021-05-07 | $2.32M derived: sum of 2 quarters · filed 2022-02-28 | $3.55M derived: sum of 3 quarters · filed 2022-02-28 | $4.74M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.45M derived: sum of 2 quarters · filed 2022-02-28 | $3.64M derived: sum of 3 quarters · filed 2022-02-28 | $4.78M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.42M derived: sum of 2 quarters · filed 2020-11-05 | $3.56M 10-Q · filed 2020-11-05 | $4.70M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.33M 10-Q · filed 2020-08-06 | $3.46M derived: sum of 3 quarters · filed 2021-03-18 | $4.58M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $1.14M 10-Q · filed 2020-05-11 | $2.27M derived: sum of 2 quarters · filed 2021-03-18 | $3.39M derived: sum of 3 quarters · filed 2021-03-18 | $4.51M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $2.25M derived: sum of 2 quarters · filed 2021-03-18 | $3.38M derived: sum of 3 quarters · filed 2021-03-18 | $4.54M 10-K · filed 2021-03-18 |
| 2018-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $2.24M derived: sum of 2 quarters · filed 2019-11-08 | $3.40M 10-Q · filed 2019-11-08 | $4.60M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $2.29M 10-Q · filed 2019-08-14 | $3.48M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2018-03-31 | $1.16M 10-Q · filed 2019-05-15 | $2.36M derived: sum of 2 quarters · filed 2020-03-16 | ||
| 2017-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $4.99M 10-K · filed 2020-03-16 | ||
| 2017-09-30 | $3.80M 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | $5.66M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |